CN104884080A - 抗凝血酶在体外膜式氧合中的用途 - Google Patents

抗凝血酶在体外膜式氧合中的用途 Download PDF

Info

Publication number
CN104884080A
CN104884080A CN201380041286.1A CN201380041286A CN104884080A CN 104884080 A CN104884080 A CN 104884080A CN 201380041286 A CN201380041286 A CN 201380041286A CN 104884080 A CN104884080 A CN 104884080A
Authority
CN
China
Prior art keywords
antithrombin
antithrombase
units per
membrane oxygenation
extracorporeal membrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380041286.1A
Other languages
English (en)
Chinese (zh)
Inventor
S.劳里
J.弗里林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
rEVO Biologics Inc
Original Assignee
GTC Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GTC Biotherapeutics Inc filed Critical GTC Biotherapeutics Inc
Publication of CN104884080A publication Critical patent/CN104884080A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201380041286.1A 2012-08-03 2013-08-02 抗凝血酶在体外膜式氧合中的用途 Pending CN104884080A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261679345P 2012-08-03 2012-08-03
US61/679,345 2012-08-03
PCT/US2013/053365 WO2014022748A1 (en) 2012-08-03 2013-08-02 The use of antithrombin in extracorporeal membrane oxygenation

Publications (1)

Publication Number Publication Date
CN104884080A true CN104884080A (zh) 2015-09-02

Family

ID=50028554

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380041286.1A Pending CN104884080A (zh) 2012-08-03 2013-08-02 抗凝血酶在体外膜式氧合中的用途

Country Status (13)

Country Link
US (1) US9511087B2 (cg-RX-API-DMAC10.html)
EP (1) EP2879697A4 (cg-RX-API-DMAC10.html)
JP (1) JP6389172B2 (cg-RX-API-DMAC10.html)
KR (1) KR20150039201A (cg-RX-API-DMAC10.html)
CN (1) CN104884080A (cg-RX-API-DMAC10.html)
AR (1) AR091977A1 (cg-RX-API-DMAC10.html)
AU (1) AU2013296240B2 (cg-RX-API-DMAC10.html)
BR (1) BR112015002321A2 (cg-RX-API-DMAC10.html)
CA (1) CA2879763C (cg-RX-API-DMAC10.html)
IL (1) IL236776A0 (cg-RX-API-DMAC10.html)
MX (1) MX2015001508A (cg-RX-API-DMAC10.html)
TW (1) TW201425332A (cg-RX-API-DMAC10.html)
WO (1) WO2014022748A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011350895B2 (en) 2010-12-30 2015-05-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Glycols as pathogen inactivating agents
CN104884080A (zh) 2012-08-03 2015-09-02 Lfb美国股份有限公司 抗凝血酶在体外膜式氧合中的用途
EP2956003A2 (en) 2013-02-13 2015-12-23 Laboratoire Français du Fractionnement et des Biotechnologies Proteins with modified glycosylation and methods of production thereof
KR20160002713A (ko) 2013-02-13 2016-01-08 라보라토이레 프란카이즈 듀 프락티온네먼트 에트 데스 바이오테크놀로지스 고도로 갈락토실화된 항-tnf-알파 항체 및 이의 용도
CA2916566A1 (fr) 2013-07-05 2015-01-08 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Matrice de chromatographie d'affinite
FR3038517B1 (fr) 2015-07-06 2020-02-28 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Utilisation de fragments fc modifies en immunotherapie
EP3388140A1 (en) * 2017-04-10 2018-10-17 Gambro Lundia AB Extracorporeal blood circuit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019193B2 (en) * 1995-02-21 2006-03-28 Gtc Biotherapeutics, Inc. Treatments using transgenic goat produced antithrombin III

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4517294A (en) 1982-03-03 1985-05-14 Genentech, Inc. Human antithrombin III
US4632981A (en) 1982-07-30 1986-12-30 Genentech, Inc. Human antithrombin III
US6727405B1 (en) 1986-04-09 2004-04-27 Genzyme Corporation Transgenic animals secreting desired proteins into milk
DE3751873T2 (de) 1986-04-09 1997-02-13 Genzyme Corp Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern
US5366894A (en) 1986-06-30 1994-11-22 Pharmaceutical Proteins Limited Peptide production
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US5439446A (en) 1994-06-30 1995-08-08 Boston Scientific Corporation Stent and therapeutic delivery system
DE4028800A1 (de) 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
DE4326665C2 (de) 1993-08-09 1995-07-13 Biotest Pharma Gmbh Verfahren zur Sterilfiltration von Milch
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US5801063A (en) 1995-05-09 1998-09-01 Grandics; Peter Device and process for the biospecific removal of heparin
US6268487B1 (en) 1996-05-13 2001-07-31 Genzyme Transgenics Corporation Purification of biologically active peptides from milk
US6528699B1 (en) 1997-02-25 2003-03-04 Genzyme Transgenics Corporation Transgenically produced non-secreted proteins
US20060264357A1 (en) 1997-04-22 2006-11-23 Zikria Bashir A Capillary membrane stabilization and reduction of tissue injury through use of biodegradable macromolecules with antioxidants and/or other chemicals
US8257724B2 (en) 1998-09-24 2012-09-04 Abbott Laboratories Delivery of highly lipophilic agents via medical devices
DE10159556A1 (de) 2001-12-05 2003-06-12 Aventis Behring Gmbh Intellect Antithrombin III zur Präventation und Therapie vaskuloproliferativer Erkrankungen
SE521676C2 (sv) 2002-01-02 2003-11-25 Dilafor Ab Användning av glykosaminoglykaner för prevention och behandling av värksvaghet vid fullgången graviditet
US20050271660A1 (en) 2002-09-06 2005-12-08 Alexion Pharmaceuticals, Inc. Nebulization of monoclonal antibodies for treating pulmonary diseases
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
AU2004271200A1 (en) 2003-09-05 2005-03-17 Gtc Biotherapeutics, Inc. Method for the production of fusion proteins in transgenic mammal milk
CA2479968A1 (en) 2004-09-01 2006-03-01 Keith R. Walley Protein c and endothelial protein c receptor polymorphisms as indicators of patient outcome
US20060292213A1 (en) 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
EP1913155A4 (en) 2005-06-23 2009-08-12 Univ British Columbia COAGULATION FACTOR III POLYMORPHISMS ASSOCIATED WITH PREDICTION RELATING TO THE RESULTS AND RESPONSE OF A SUBJECT TO THERAPY
WO2007014244A2 (en) 2005-07-25 2007-02-01 Gtc Biotherapeutics, Inc. Method of purifying recombinant human antithrombin to enhance the viral and prion safety profile
ES2642787T3 (es) 2005-10-21 2017-11-20 Lfb Usa, Inc. Anticuerpos con actividad de citotoxicidad celular dependiente de anticuerpos mejorada, métodos para su producción y uso
US20070292407A1 (en) 2005-12-12 2007-12-20 The Board Of Trustees Operating Michigan State University Methods of treatment for meconium aspiration syndrome
US7531632B2 (en) 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
US8173860B2 (en) 2006-04-21 2012-05-08 Gtc Biotherapeutics, Inc. Non-human transgenic mammal expressing a human FcRn on its mammary gland cells and expressing a transgenic protein-human Fc-domain fusion
WO2009097584A1 (en) 2008-01-30 2009-08-06 Proteogenix, Inc. Maternal serum biomarkers for detection of pre-eclampsia
US20110082083A1 (en) 2009-04-10 2011-04-07 Gtc Biotherapeutics, Inc. Formulations of liquid stable antithrombin
US8551096B2 (en) 2009-05-13 2013-10-08 Boston Scientific Scimed, Inc. Directional delivery of energy and bioactives
AU2012278836B2 (en) 2011-07-07 2016-03-10 Lfb Usa, Inc. Formulations that stabilize proteins
TW201400499A (zh) 2012-03-12 2014-01-01 Revo Biolog Inc 抗凝血酶用於治療妊娠毒血症之用途
CN104884080A (zh) 2012-08-03 2015-09-02 Lfb美国股份有限公司 抗凝血酶在体外膜式氧合中的用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019193B2 (en) * 1995-02-21 2006-03-28 Gtc Biotherapeutics, Inc. Treatments using transgenic goat produced antithrombin III

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AGATI S.等: "Use of a Novel Anticoagulation Strategy During ECMO in a Pediatric Population: Single-Center Experience", 《ASAIO JOURNAL》 *
NIEBLER R.A.等: "Antithrombin Replacement During Extracorporeal Membrane Oxygenation", 《ARTIFICIAL ORGANS》 *

Also Published As

Publication number Publication date
JP2015524823A (ja) 2015-08-27
EP2879697A4 (en) 2016-01-20
MX2015001508A (es) 2015-04-08
AR091977A1 (es) 2015-03-11
KR20150039201A (ko) 2015-04-09
CA2879763A1 (en) 2014-02-06
IL236776A0 (en) 2015-03-31
AU2013296240B2 (en) 2018-05-17
US9511087B2 (en) 2016-12-06
TW201425332A (zh) 2014-07-01
WO2014022748A1 (en) 2014-02-06
BR112015002321A2 (pt) 2019-10-22
JP6389172B2 (ja) 2018-09-12
CA2879763C (en) 2020-12-01
US20140194360A1 (en) 2014-07-10
AU2013296240A1 (en) 2015-02-12
EP2879697A1 (en) 2015-06-10

Similar Documents

Publication Publication Date Title
JP6389172B2 (ja) 体外式膜型人工肺におけるアンチトロンビンの使用
CN107405391B (zh) 治疗外伤患者中的出血的血小板微粒的全身和局部应用
KR100885601B1 (ko) 고 활성 및 감소된 부작용을 가진 재조합에리트로포이에틴의 치료 용도
ES2230624T3 (es) Composicion farmaceutica que comprende un compuesto que tiene actividad anti-xa y un compuesto antagonista de la agregacion plaquetaria.
EP3506915B1 (en) Human blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
AU2013203512B2 (en) The use of antithrombin in the treatment of pre-eclampsia
US20100298223A1 (en) Fibrinogen for treatment of bleeding in trauma and platelet disorders
US20180207246A1 (en) Compositions and methods for treating post-operative complications of cardiopulmonary surgery
EA010650B1 (ru) Защищающие ткань цитокины для лечения и профилактики сепсиса и образования спаек
Ashikhmina et al. Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest
TWI899198B (zh) 包含15-hepe之組成物及治療或預防血液學病症及/或相關疾病之方法
EP2476426A1 (en) Treatment and prevention of symptoms of metabolic syndrome
JP2017109987A (ja) ＥｒｂＢ４＋炎症性マクロファージによって媒介される疾患の治療方法
JP6289511B2 (ja) 羊水塞栓の治療剤
WO2021157619A1 (ja) 膵液瘻の予防または治療剤
JP2009521513A (ja) 治療の方法
WO2023192779A2 (en) Combined prevention and treatment of patients with respiratory diseases caused by rna viral infections
JP2026516054A (ja) 敗血症性ショックの治療のための組成物及び方法
WO2011115479A1 (en) Use of anticoagulants in the production of recombinant proteins in the milk of transgenic animals
JP2007262027A (ja) Ａｔ−ｉｉｉによる内因性ｉｇｆ−１の産生誘導剤

Legal Events

Date Code Title Description
PB01 Publication
EXSB Decision made by sipo to initiate substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20150902

RJ01 Rejection of invention patent application after publication